Cargando…
miR‐181a induces sorafenib resistance of hepatocellular carinoma cells through downregulation of RASSF1 expression
Sorafenib, a multi‐kinase inhibitor, is the only standard clinical drug for patients with advanced hepatocellular carcinoma (HCC); however, development of sorafenib resistance in HCC often prevents its long‐term efficacy. Therefore, novel targets and strategies are urgently needed to improve the ant...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021022/ https://www.ncbi.nlm.nih.gov/pubmed/27384977 http://dx.doi.org/10.1111/cas.13006 |